Glucotrack, Inc. Reports Progress and Financial Results

Glucotrack, Inc. ( (GCTK) ) has released its Q2 earnings. Here is a breakdown of the information Glucotrack, Inc. presented to its investors.

Glucotrack, Inc. is a Delaware-based company specializing in the development of an implantable continuous blood glucose monitor (CBGM) for diabetes patients, offering a unique solution with no on-body wearable component and minimal calibration requirements. In its latest earnings report for the quarter ending June 30, 2025, Glucotrack highlighted significant progress in its clinical studies and financial activities. The company reported a net loss of $11.6 million for the six-month period, reflecting increased operating expenses, particularly in research and development and general administration. Despite these losses, the company successfully raised $10.7 million through public offerings, bolstering its cash reserves to $9.6 million. Glucotrack’s strategic focus remains on advancing its CBGM technology, having completed a successful first-in-human clinical study and preparing for a long-term study outside the U.S. The company is also in discussions with the FDA for a pre-investigational device exemption submission, aiming to secure approval for future clinical trials in the U.S. Looking ahead, Glucotrack’s management is optimistic about its technology’s potential, although it acknowledges the need for additional financing to achieve commercialization and sustain operations.